Details for Patent: 8,404,700

Which drugs does patent 8,404,700 protect, and when does it expire?

Patent 8,404,700 protects TURALIO and is included in one NDA.

This patent has forty-eight patent family members in thirty-five countries.

Summary for Patent: 8,404,700

Title:	Compounds modulating c-fms and/or c-kit activity and uses therefor
Abstract:	Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.
Inventor(s):	Ibrahim; Prabha N. (Mountain View, CA), Artis; Dean R. (Kensington, CA), Bremer; Ryan (Emeryville, CA), Wu; Guoxian (Foster City, CA), Zhu; Hongyao (Berkeley, CA), Nespi; Marika (Berkeley, CA), Zhang; Chao (Moraga, CA), Zhang; Jiazhong (Burlingame, CA)
Assignee:	Plexxikon Inc. (Berkeley, CA)
Application Number:	13/546,923
Patent Claim Types: see list of patent claims	Composition; Compound; Device;

Drugs Protected by US Patent 8,404,700

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-002	Oct 14, 2022		RX	Yes	No				Y
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		DISCN	Yes	No				Y

International Family Members for US Patent 8,404,700

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	063878
Australia	2007323644
Brazil	PI0721137
Canada	2670362